Roche Holding AG is considering options for its diabetes-care business including a sale, Bloomberg reported, citing people familiar with the matter.
The alternatives for the unit could include a partial sale or spinoff and the sale could fetch as much as $5 billion, Bloomberg also reported.
The Swiss drugmaker had said last year that it has no plans to sells its diabetes testing business.
Johnson & Johnson said last week that it is looking to divest its diabetes division, while Bayer AG sold its diabetes business to KKR and Panasonic in 2015, for $1.1 billion.
Roche was not immediately available for comment outside regular business hours.
By Parikshit Mishra
Source: Reuters
Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.
Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.
Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.